SEC Comment Letter 0000000000-23-010931 to ZEVRA THERAPEUTICS, INC. (ZVRA)
ZEVRA THERAPEUTICS, INC.
Date: Oct. 4, 2023 · CIK: 0001434647 · Accession: 0000000000-23-010931
AI Filing Summary & Sentiment
File numbers found in text: 333-274758
Letter
United States securities and exchange commission logo October 4, 2023 R. LaDuane Clifton, CPA Chief Financial Officer, Secretary and Treasurer Zevra Therapeutics, Inc. 1180 Celebration Boulevard, Suite 103 Celebration, FL 34747 Re:Zevra Therapeutics, Inc. Registration Statement on Form S-4 Filed September 29, 2023 File No. 333-274758 Dear R. LaDuane Clifton: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stephanie M. Hosler, Esq.
Show Raw Text
United States securities and exchange commission logo
October 4, 2023
R. LaDuane Clifton, CPA
Chief Financial Officer, Secretary and Treasurer
Zevra Therapeutics, Inc.
1180 Celebration Boulevard, Suite 103
Celebration, FL 34747
Re:Zevra Therapeutics, Inc.
Registration Statement on Form S-4
Filed September 29, 2023
File No. 333-274758
Dear R. LaDuane Clifton:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Stephanie M. Hosler, Esq.